In addition, targeted treatments for other genetic variations in NSCLC are currently under development, including RET fusion [11], human epidermal growth factor receptor 2 (HER2) insertion (NCT04382300), or MET exon 14 skipping mutations (NCT02897479). Here, MET is linked to non-small cell lung carcinoma.